You can buy or sell Lantheus and other stocks, options, ETFs, and crypto commission-free!
Lantheus Holdings, Inc. engages in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its products are used by cardiologists, nuclear physicians, radiologists, internal medicine physicians, sonographers and technologists working in a variety of clinical settings. Read More The firm's operates through the following geographical segments: U.S. and International. The U.S. segment produces and markets medical imaging agents and products throughout the U.S. This segment sells its products to radio pharmacies, integrated delivery networks, hospitals, clinics and group practices. The International segment operations consist of production and distribution activities in Puerto Rico and direct distribution activities in Canada. The company was founded in 1956 and is headquartered in North Billerica, MA.
North Billerica, Massachusetts
52 Week High
52 Week Low
Lantheus Announces Upcoming Retirement of Chief Medical Officer in September 2019 and Promotion of Senior Vice President, Technical Operations to Chief Operations Officer
Lantheus Holdings, Inc. (the "Company”) (NASDAQ: LNTH), parent company of Lantheus Medical Imaging, Inc. ("LMI”), a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, today announced that Cesare Orlandi, M.D., Chief Medical Officer, will retire from the Company on September 2, 2019. In addition, John Bolla, the Company’s Senior Vice President, Technical Operations, has been promoted to the newly created position of Chief Operations Offic...
Yahoo FinanceMar 21
Top Ranked Momentum Stocks to Buy for March 21st
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, March 21st: Bio-Rad Laboratories, Inc. (BIO): This manufacturer of products and solutions for life science research has a Zacks Rank #1 (Strong Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 5.6% over the last 60 days. Bio-Rad Laboratories, Inc. Price and Consensus Bio-Rad Laboratories, Inc. Price and Consensus More Bio-Rad Laboratories, Inc. price-consensus-c...
Expected May 1, After Hours